MEDDIC for Fintech – Go to Market

A successful demo is not a qualified opportunity. In a bank, insurer or NBFC, the distance between product enthusiasm and a purchase order is filled with business owners, architecture teams, risk, compliance, information security, procurement and investment committees.

MEDDIC forces a simple discipline: replace optimism with evidence. It asks whether the deal has a measurable outcome, a buyer with real authority, known evaluation rules, a navigable approval process, pain important enough to act on, and an insider willing to help you win.

The central idea
Fintech deals do not die because the product is weak. They die because the seller never discovered how the institution buys.
01 — The six qualification tests

M — Metrics

Turn “better” into a number the institution can defend.

Metrics connect product capability to the buyer’s operating plan: more approved customers, fewer manual reviews, lower fraud leakage, faster turnaround or additional processing capacity without another hiring cycle.

Establish the baseline, target improvement, volume affected and financial value of one improved unit. Then agree who will validate the result after implementation. If the buyer cannot explain how value will be measured, the business case is still a hypothesis.

RevenueConversion, approval, cross-sell and renewal
CostManual review, onboarding, servicing and FTE capacity
RiskFraud loss, false positives, delinquencies and exceptions
ExperienceTurnaround, abandonment, complaints and resolution
Worked business case

A digital lender processes 500,000 applications a year.

Completion rate
52% → 60%
Incremental completions
40,000
Disbursal rate
20%
Incremental loans
8,000
Contribution per loan
₹5,000
Annual contribution
₹4 crore
Discovery questionWhat improvement would make this initiative impossible to deprioritise?
02 — Authority

E — Economic Buyer

Find the person who can fund the outcome and accept its risk.

In fintech, the CIO is often an evaluator rather than the economic buyer. The real authority usually sits with the executive who owns the P&L, cost base, regulatory exposure or transformation outcome. Your sponsor may love the platform and still lack the authority to protect its budget.

SolutionLikely economic buyerPrimary concern
Digital lendingBusiness CEO / Head of LendingGrowth and credit quality
Fraud platformCRO / Head of FraudLoss avoided and false positives
Collections AIHead of CollectionsRecovery rate and cost-to-collect
Voice AICOO / Service HeadContainment, compliance and CX
Regulatory reportingCFO / Compliance HeadAccuracy, control and auditability

Economic-buyer validation means more than securing a meeting. You need explicit agreement on the problem, expected outcome, funding mechanism and decision date. If access is permanently blocked, treat that as deal risk—not a calendar inconvenience.

03 — Evaluation

D — Decision Criteria

Understand the rules—and shape them before the RFP freezes.

A regulated institution rarely selects technology on product capability alone. The evaluation spans business value, architecture, compliance, security and vendor resilience. Learn which requirements are mandatory, which are weighted and which have quietly been designed around an incumbent.

Business

ROI, adoption, time to market, flexibility and total cost

Technology

APIs, core integration, scale, availability, latency and DR

Risk & compliance

Residency, consent, explainability, audit trail and regulatory fit

Vendor

References, stability, local support, roadmap and liability

Late-stage warning

If you first discover the criteria inside the RFP, another vendor may already have written the exam.

04 — Route to signature

D — Decision Process

Convert institutional complexity into owners, gates and dates.

Map the formal approval path and the paper process underneath it. A fintech vendor can win the product evaluation and still miss the quarter because vendor empanelment, security exceptions, liability language or committee calendars were discovered too late.

01Business case
02Architecture
03Risk + InfoSec
04Proof of value
05Legal + procurement
06Committee + PO

Build a mutual action plan with one named owner and a dated exit criterion for every stage. “InfoSec review in progress” is not a plan. “CISO exception review on 24 August; evidence pack owned by the solution architect” is.

05 — Urgency

I — Identify Pain

Trace a symptom to its executive consequence.

“KYC is manual” describes a process. It does not explain why the institution must act. Strong qualification connects operational friction to business damage and then to an executive commitment.

Operational painManual review creates slow onboarding
Business pain28% abandonment destroys acquisition spend
Executive painQuarterly disbursal target and board commitment are at risk

The best urgency is tied to a forcing event: a regulatory deadline, expiring incumbent contract, board target, product launch, audit observation or visible loss of market share. Pain without consequence creates a long pipeline—not a purchase.

06 — Internal advocacy

C — Champion

Distinguish a friendly contact from someone who will sell internally.

A champion has influence, gains from the outcome and demonstrates action. They explain how decisions are really made, expose opposition, coach you before executive meetings and advocate when you are not in the room. Enthusiasm without action is not championship.

The champion test
  • Will they help build the internal business case?
  • Will they share the real approval sequence and political risks?
  • Will they arrange access to the economic buyer?
  • Will they tell you where you stand against the incumbent?
  • Will they defend the decision when you are absent?
Deal control

MEDDIC qualification scorecard

Score evidence—not seller confidence. Every category receives 0–3 points, producing a maximum score of 18.

0Unknown
1Assumed
2Confirmed once
3Validated with authority
MetricsBaseline, target, value and measurement owner
Economic buyerIdentity, access, priority and funding support
Decision criteriaDocumented business, technical and risk requirements
Decision processStakeholders, stages, committees, dates and paper process
Identify painQuantified impact, consequence and forcing event
ChampionInfluential advocate demonstrating internal action
15–18Strong, evidence-backed opportunity
11–14Viable deal with identifiable gaps
7–10High-risk opportunity
0–6Lead or pipeline inflation
The regulated-market extension

Why fintech sellers should use MEDDPICC

MEDDIC is the foundation. For complex bank and insurance sales, extend it with three realities that repeatedly move closing dates.

PPaper Process — contracting, legal, empanelment, InfoSec evidence and the purchase order.
IImplicated Pain — the organizational and personal consequence of leaving the problem unresolved.
CCompetition — rival vendors, the incumbent, internal build, outsourcing and doing nothing.
Before the forecast call

The 12-question deal review

  1. 01What business metric changes if we win?
  2. 02What is the validated annual value?
  3. 03Who owns that outcome and its budget?
  4. 04Has the economic buyer confirmed the problem?
  5. 05What are the three highest-weight decision criteria?
  6. 06Which requirement could disqualify us?
  7. 07What approval gates remain, with dates and owners?
  8. 08When does the investment committee meet?
  9. 09What happens if the institution does nothing?
  10. 10What forcing event creates urgency?
  11. 11What has our champion done—not said—this week?
  12. 12Why will we win against the incumbent or no decision?
Final perspective

A forecast is a claim.
MEDDIC gives it evidence.

The goal is not to complete a CRM template. It is to expose what must become true for the institution to buy—and act on those gaps while there is still time to change the outcome.

Leave a Comment

Your email address will not be published. Required fields are marked *